Harmony Biosciences Holdings vs Supernus Pharmaceuticals
Harmony Biosciences Holdings is the larger business, with $868m of revenue in fiscal 2025 against $719m for Supernus Pharmaceuticals (1.2 times as much). Harmony Biosciences Holdings grew faster (21.5% against 8.6%). Harmony Biosciences Holdings kept more of each dollar of sales as profit: a net margin of 18.3% against -5.4%. Supernus Pharmaceuticals carries less debt relative to equity (0.0% against 19.0%).
| Latest fiscal year | Harmony Biosciences HoldingsHRMY, 2025 | Supernus PharmaceuticalsSUPN, 2025 |
|---|---|---|
| Revenue | $868m | $719m |
| Revenue growth | 21.5% | 8.6% |
| Net income | $159m | −$38.5m |
| Operating margin | 24.0% | -8.7% |
| Net margin | 18.3% | -5.4% |
| Return on equity | 20.8% | -3.7% |
| Free cash flow | $348m | $46.0m |
| Cash | $753m | $128m |
| Total debt | $165m | $0 |
| Debt to equity | 19.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 293 | 778 |
| Market value | $2.14bn | $1.65bn |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | 93 (Strong) | 69 (Moderate) |
| Insider trades, 12 months | 0 buys, 13 sales | 0 buys, 20 sales |